Bactroban cream QUAliTATIVE AND QUANTITATIVE COMPOSITION (active ingredient only) :
Mupirocin calcium equivalent to 2% wlw Mupirocin free acid.
Bactroban cream PHARMACEUTICAL FORM :
White cream of homogeneous appearance.
Bactroban cream CLINICAL PARTICULARS :
Therapeutic indications: Bactroban CREAM is indicated for the topical treatment 0fsecondarily infected traumatic lesions such as small lacerations, Sutured wounds or abrasions (up to 10 cm in length or 100 cm> in area), due to susceptible strains of Staphylococrus aureus and streptococcus pyogenes.
Bactroban cream Dosage :
three times a day for up to 10 days, deperdi1g 0n the response. Patients not showing a clinical response within 3 to 5 days should be re evaluated.
The duration of treatment should not exceed 10 days.
Heparic impairment No dosage adjustment is necessary.
Renal impairment No dosage adjustment is necessary.
Bactroban cream Method of administration :
A thin layer of cream should be applied to the affeaed area with a piece 0f clean Cotton wool or gauze swab. The treated area may be Covered by a dressing. Do not mix with other preparations as there is a risk of dilution, resulting in a reduction in the antilacterial activity and potential loss of stability of the mupirocin in the cream.
Bactroban cream Contra-indications :
Bactroban CREAM should not be given to patients with ahistay of hypersensitivity to any of its constituents.
Special warnings and special precautions for use.
Bactroban cream Pregnancy and lactation :
Use in pregnancy .
Adequate Iunan data on use during pregnancy are not avaliable, animal studies have not identified any risk to pregency or embryo foetal development Mupirocin shoud only be used in pregenancy when the poIfntiii benefits outweigh the potential risks associated with treatment.
Use in lactation:
Adequate human and animaI data on use during lactation are not available. if a cracked nipple is to be treated, it shoud be thoroughly washed prior to breast feeding.
Bactroban cream Undesirable effects :
The following convention has been used for the classification of frequency common 1/100 and 1/10
Skin and subcutaneous tissue disorders:
Common: Cutaneous hypersensitivity reactions
Bactroban cream Overdose :
The toxicity of Mupirocin is very low in the event of accidental ingestion of the cream symptomatic treatment should be given
Bactroban cream PHARMACOlOGICAl PROPERTIES :
Mupirocin is a novel antibiotic produced throogh fermentation by pseudomonas fluorescens mupirocin inhibits isoleucyl transfer RNA synthetase, thereby arresting bacterial protein synthesis. due to this particular mode of action and its unique chemical structure, Mupirocin does not shaw any cross-resistance with other clinically available antibiotics.
Mupirocin has bacteriostatic properties at minimum inhibitory concentrations and bactericidal properties at the higler concentrations reached when applied locally
Mupirorin is a topical antibacterial agent showing in vivo activity against staphylococcus aureus (including methicillin resistant strains) s.epidemidis and beta-haemolytic streptococcus spedes. The in vitro spectrum of activity includes the following bacteria
– staphlococcus aureus (including beta lactamase producing strains and methicillin resistant strains)
– staphlococcus epidemidis (including beta lactamase producing and methicillin resistant strains)
– Other coagulase negative staphylococci (including methicillin resistant strains)
– streptococcus species
Aerobic Gram-negative :
– Haemophilus influenzae
– Neisserie gonorrhoeae
– Moraxella catarrhalis
– Pasteurella multocida
Bactroban cream Pharmacokintic properties :
Systemic absorption of Mupirocin through intact human skin is low although it may occur through broken diseased skin however clinical trials have shown that when given systemically it is metabolised to the microbiologically inactive metabolite monic acid and rapidIy excreted by the kidney.
Nature and contents of container :
Squeezable aluminium tubes with ascrew cap containing 15 g.
Instructions for use/handling :
Any product remaining at the end of treatment should be discarded.
Manufactured by :
Glaxo operations UK limited
Member of the GIaxosmithKline group of companies.